JPMorgan Chase & Co. Raises United Therapeutics (NASDAQ:UTHR) Price Target to $300.00

United Therapeutics (NASDAQ:UTHR) had its price objective upped by JPMorgan Chase & Co. from $280.00 to $300.00 in a report released on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on UTHR. HC Wainwright reaffirmed a buy rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Leerink Partnrs reaffirmed an outperform rating on shares of United Therapeutics in a research note on Monday, February 5th. StockNews.com raised shares of United Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, May 16th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an overweight rating in a research report on Thursday, March 7th. Finally, Oppenheimer lifted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $309.44.

United Therapeutics Trading Up 0.0 %

Shares of UTHR stock opened at $276.50 on Tuesday. United Therapeutics has a twelve month low of $204.44 and a twelve month high of $279.98. The company has a market capitalization of $12.26 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 4.17 and a beta of 0.54. The firm has a 50-day moving average price of $246.55 and a 200 day moving average price of $233.68. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.86 earnings per share. Research analysts forecast that United Therapeutics will post 24.2 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,166.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, Director Martine A. Rothblatt sold 1,468 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $275.85, for a total value of $404,947.80. Following the transaction, the director now owns 130 shares in the company, valued at approximately $35,860.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total value of $835,380.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,166.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 153,528 shares of company stock valued at $37,060,321. Company insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the last quarter. Formidable Asset Management LLC increased its position in shares of United Therapeutics by 1.5% in the 3rd quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company’s stock worth $821,000 after purchasing an additional 53 shares during the last quarter. MBM Wealth Consultants LLC raised its stake in shares of United Therapeutics by 2.7% in the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 59 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in United Therapeutics by 1.6% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after buying an additional 61 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC lifted its holdings in United Therapeutics by 6.1% during the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock worth $288,000 after buying an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.